At least 13 compounds are in development for inner ear disorders, including hearing loss, Meniere's disease, tinnitis and vertigo. The most advanced is neramexane to treat tinnitis from Merz GmbH & Co. KGaA and partner Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569). Source: BCIQ: BioCentury Online Intelligence

Company

Product

Description

Indication

Status

Merz GmbH & Co. KGaA/ Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569)

Neramexane

NMDA receptor antagonist

Subjective tinnitis

Ph III